trial · primary record
Polatuzumab Vedotin
Mantle Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2038-01-01 |
| Primary endpoint | Positron emission tomography complete response (CR) rate |
| Registry ID | NCT07910435 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:09.157Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07910435
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.